The issue of resistant hypertension in chronic glomerulonephritis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Resistant hypertension is common among patients with kidney disease. The article describes the resistant hypertension in chronic kidney disease, discusses the importance of immune mechanisms involved in the development of resistant hypertension. Resistant hypertension worsens the prognosis of glomerulonephritis and speeds up the development of CKD dialysis stage.

参考

  1. Тареева И.Е. Нефрология. Руководство для врачей. М., 2000. 688 с.
  2. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J. Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A.,Sleight P., Viigimaa M., Waeber B., Zannad F., Redon J., Dominiczak A., Narkiewicz K., Nilsson P.M., Burnier M., Viigimaa M., Ambrosioni E., Caufield M., Coca A., Olsen M.H., Schmieder R.E., Tsioufis C., van de Borne P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Clement D.L., Coca A., Gillebert T.C., Tendera M., Rosei EA., Ambrosioni E., Anker S.D., Bauersachs J., Hitij J.B., Caulfield M., De Buyzere M., De Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Hoes A.W., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Olsen M.H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B.A., Reiner Z., Rydén L., Sirenko Y., Stanton A., Struijker-Boudier H., T sioufis C., van de Borne P., Vlachopoulos C., Volpe M., Wood D.A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
  3. Hebert L.A., Kusek J.W., Greene T., Agodoa L.Y., Jones C.A., Levey A.S., Breyer J.A., Faubert P., Rolin H.A., Wang S.R. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 30(3): 428-435.
  4. Judd E., Calhoun D.A. Management of Hypertension in CKD: Beyond the Guidelines. Adv. Chronic Kidney Dis. 2015; 22(2): 116-122.
  5. Кутырина И.М., Мартынов С.А., Швецов М.Ю. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Терапевтический архив. 2004; 9: 10-15.
  6. Sato W., Sato Y. Midkine in nephrogenesis, hypertension and kidney diseases. Br. J. Pharmacol. 2014; 171(4): 879-887.
  7. Campese V.M. Pathophysiology of resistant hypertension in chronic kidney disease. Semin. Nephrol. 2014; 34(5): 571-576.
  8. Denolle T., Chamontin B., Doll G., Fauvel J.P., Girerd X., Herpin D., Vaïsse B., Villeneuve F., Halimi J.M. Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Presse Med. 2014; 43(12): 1325-1331.
  9. Drexler Y.R., Bomback A.S. Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. Nephrol. Dial. Transplant. 2014; 29(7): 1327-1335.
  10. Sarafidis P.A., Bakris G.L. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 2008; 52(22): 1749-1757.
  11. Muntner P., Davis B.R., Cushman W.C., Bangalore S., Calhoun D.A., Pressel S.L., Black H.R., Kostis J.B., Probstfleld J.L., Whelton P.K., Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014; 64(5): 1012-1021.
  12. Tanner R.M., Calhoun D.A., Bell E.K., Bowling C.B., Gutiérrez O.M., Irvin M.R., Lackland D.T., Oparil S., Warnock D., Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin. J. Am. Soc. Nephrol. 2013; 8(9): 1583-1590.
  13. Кутырина И.М., Швецов М.Ю., Фомин В.В. Клинические рекомендации по диагностике и лечению почечной артериальной гипертензии. 2014. 51 с. 14.
  14. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая нефрология. 2014; 2: 4-29.
  15. Sarafidis P.A., Georgianos P.I., Zebekakis P.E. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin. Nephrol. 2014; 34(5): 483-491.
  16. Кутырина И.М., Швецов М.Ю. Возможности лечения почечной артериальной гипертонии. Качество жизни. Медицина. 2006; 4(15): 78-89.
  17. Мухин Н.А., Фомин С.В., Моисеев С.В., Швецов М.Ю. Нефрогенная артериальная гипертония: эволюция лечения. Терапевтический архив. 2005; 8: 70-78. 18.
  18. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16(1): 15-89.
  19. Чазова И.Е., Ратова Л.Г., Бойцов С.А. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-26.
  20. Nakamura M., Shirai A., Yamazaki O., Satoh N., Suzuki M., Horita S., Yamada H., Seki G. Roles of Renal Proximal Tubule Transport in Acid/Base Balance and Blood Pressure Regulation. Biomed Res. Int. 2014; 2014: 1-7.
  21. Pirkle J.L., Freedman B.I. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. Minerva Urol. Nefrol 2013; 65(1): 37-50.
  22. McDonough A.A. Mechanisms of proximal tubule sodium transport regulation that link extracellular fluid volume and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 298(4): 851-861.
  23. Coffman T.M. The inextricable role of the kidney in hypertension. J. Clin. Invest. 2014; 124(6): 2341-2347.
  24. Lv J. Neal B., Ehteshami P., Ninomiya T., Woodward M., Rodgers A., Wang H., MacMahon S., Turnbull F., Hillis G., Chalmers J., Perkovic V. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012; 9(8): e1001293.
  25. Pao A.C. Update on the Guytonian view of hypertension. Curr. Opin. Nephrol. Hypertens. 2014; 23(4): 391-398. 26.
  26. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012; 2(5).
  27. Appel L.J., Wright J.T. Jr., Greene T., Agodoa L.Y., Astor B.C., Bakris G.L., Cleveland W.H., Charleston J., Contreras G., Faulkner M.L., Gabbai F.B., Gassman J.J., Hebert L.A., Jamerson K.A., Kopple J.D., Kusek J.W., Lash J.P., Lea J.P., Lewis J.B., Lipkowitz M.S., Massry S.G., Miller E.R., Norris K., Phillips R.A., Pogue V.A., Randall O.S., Rostand S.G., Smogorzewski M.J., Toto R.D., Wang X. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 2010; 363(10): 918-929.
  28. Levey A.S., Coresh J., Greene T.,Marsh J., Stevens L.A., Kusek J.W., Van Lente F. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007; 53(4): 766-772.
  29. Sica D.A. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? J. Clin. Hypertens. (Greenwich). 2003; 5(2): 159-167.
  30. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., Lackland D.T., LeFevre M.L., MacKenzie T.D., Ogedegbe O., Smith S.C. Jr., Svetkey L.P., Taler S.J., Townsend R.R., Wright J.T. Jr., Narva A.S., Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5): 507-520.
  31. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., de Zeeuw D., Shahinfar S., Toto R., Levey A.S. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 2003; 139(4): 244-252.
  32. Ермоленко В.М., Филатова Н.Н. О целевых значениях артериального давления у больных ХБП (Обзор литературы). Нефрология и диализ. 2010; 4: 238-241.
  33. Кузьмин О.Б., Пугаева М.О., Жежа В.В. Нефропротективная терапия гипертензивных больных с хронической болезнью почек: есть ли в ней место для ß-адреноболкаторов третьего поколения и агонистов Ii-имидазолиновых рецепторов? Нефрология. 2006; 10(2): 18-26.
  34. Ruggenenti P., Perna A., Loriga G.,Ganeva M., Ene-Iordache B., Turturro M., Lesti M., Perticucci E., Chakarski I.N., Leonardis D., Garini G., Sessa A., Basile C., Alpa M., Scanziani R., Sorba G., Zoccali C., Remuzzi G. Bloodpressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365(9463): 939-946.
  35. Ермоленко В.М., Николаев А.Ю., Филатова Н.Н. Ингибиция ренинангиотензин-альдостероновой системы и нефропротекция. Нефрология. 2011; 2: 30-42.
  36. Maione A., Navaneethan S.D., Graziano G., Mitchell R., Johnson D., Mann J.F., Gao P., Craig J.C., Tognoni G., Perkovic V., Nicolucci A., De Cosmo S., Sasso A.,Lamacchia O., Cignarelli M., Manfreda V.M., Gentile G., Strippoli G.F. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 2011; 26(9): 2827-2847.
  37. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsärinne K., Oto A., Parkhomenko A., Piegas L.S., Svendsen T.L., Teo K.K., Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet. 2008; 372(9638): 547-553.
  38. Li X., Yang M.S. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and metaanalysis. PLoS One. 2014; 9(10): e109834.
  39. Takenaka T., Sueyoshi K., Arai J., Watanabe Y., Takane H., Ohno Y., Suzuki H. Calcium channel blockers suppress daily variations of blood pressure in hypertensive patients with end-stage renal diseases. Clin. Exp. Hypertens. 2014; 36(2): 78-82.
  40. Tani S., Takahashi A., Nagao K., Hirayama A. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine. Int. Heart J. 2014; 55(6): 519-25.
  41. Kuriyama S., Yokoyama K., Hara Y., Sugano N., Yokoo T., Hosoya T. Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clin. Exp. Nephrol. 2014; 18(5): 821-830.
  42. DiBona G.F. Sympathetic nervous system and the kidney in hypertension. Curr. Opin. Nephrol. Hypertens. 2002; 11(2): 197-200.
  43. Tomiyama H., Yamashina A. Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. Int. J. Hypertens. 2014; 2014: 919256.
  44. Mene P. Calcium channel blockers: what they can and what they can't do. Nephrol. Dial. Transplant. 1997; 12(1): 25-28.
  45. Игнатенко Г.А., Мухин И.В., Кошелева Е.Н. Влияние бета-адреноблокаторов на маркеры прогрессирования хронического гломерулонефрита у гипертензивных больных с сохранной и сниженной функцией почек. Нефрология. 2005; 9(4): 53-58.
  46. Weber M.A.,Schiffrin E.L., White W.B., Mann S.,Lindholm L.H.,Kenerson J.G., Flack J.M., Carter B.L., Materson B.J., Ram C.V., Cohen D.L., Cadet J.C., Jean-Charles R.R., Taler S., Kountz D., Townsend R.R., Chalmers J., Ramirez A.J., Bakris G.L., Wang J., Schutte A.E., Bisognano J.D., Touyz R.M., Sica D., Harrap S.B. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Clin. Hypertens (Greenwich). 2014; 16(1): 14-26.
  47. Borrelli S., Borrelli S., De Nicola L., Stanzione G., Conte G., Minutolo R. Resistant hypertension in nondialysis chronic kidney disease. Int. J. Hypertens. 2013; 2013: 929183.
  48. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr., Jones D.W., Materson B.J., Oparil S., Wright J.T. Jr., Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560-2572.
  49. Boggia J., Li Y., Thijs L., Hansen T.W., Kikuya M., Björklund-Bodegard K., Richart T., Ohkubo T., Kuznetsova T., Torp-Pedersen C., Lind L., Ibsen H., Imai Y., Wang J., Sandoya E., O'Brien E., Staessen J.A. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007; 370(9594): 1219-1229.
  50. Donazzan L., Ewen S.,Papademetriou V., Linicus Y., Linz D., Böhm M., Mahfoud F. Drug therapy for the patient with resistant hypertension. Future Cardiol. 2015; 11(2): 191-202.
  51. Лямина Н.П., Смит М.Л., Наливаева А.В., Лямина С.В., Манухина Е.Б.,Сенчихин В.Н., Липчанская Т.П., Котельникова Е.В., Дауни Г.Ф. Прогностическая ценность теста 30-секундной задержки дыхания в диагностике маскированной артериальной гипертензии у лиц молодого возраста. Фарматека. 2015; 9: 63-67.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##